These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36001142)

  • 41. Immunotherapy for ocular myasthenia gravis: an observational study in Japan.
    Narita T; Nakane S; Nagaishi A; Minami N; Niino M; Kawaguchi N; Murai H; Kira JI; Shimizu J; Iwasa K; Yoshikawa H; Hatanaka Y; Sonoo M; Shimizu Y; Matsuo H
    Ther Adv Neurol Disord; 2023; 16():17562864231163819. PubMed ID: 37051222
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis.
    Zhao R; Wang Y; Huan X; Zhong H; Zhou Z; Xi J; Da Y; Lei L; Chang T; Ruan Z; Luo L; Li S; Yang H; Li Y; Luo S; Zhao C
    J Transl Med; 2021 Jun; 19(1):285. PubMed ID: 34193193
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical predictors for the prognosis of myasthenia gravis.
    Wang L; Zhang Y; He M
    BMC Neurol; 2017 Apr; 17(1):77. PubMed ID: 28420327
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Prognosis of thymectomy in treatment of ocular myasthenia gravis and relevant influencing factors].
    Deng Y; Zhang X
    Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(27):1922-5. PubMed ID: 19953918
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic factors and health-related quality of life in ocular Myasthenia Gravis (OMG).
    Ariatti A; Stefani M; Miceli P; Benuzzi F; Galassi G
    Int J Neurosci; 2014 Jun; 124(6):427-35. PubMed ID: 24228829
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Response to treatment in pediatric ocular myasthenia gravis.
    Xu L; Castro D; Reisch JS; Iannaccone ST
    Muscle Nerve; 2020 Feb; 61(2):226-230. PubMed ID: 31650555
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Myasthenia gravis: MuSK MG, late-onset MG and ocular MG.
    Deymeer F
    Acta Myol; 2020 Dec; 39(4):345-352. PubMed ID: 33458590
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Spotlight on MuSK positive myasthenia gravis: clinical characteristics, treatment and outcomes.
    Huang Q; Li F; Zhao S
    BMC Neurol; 2022 Mar; 22(1):73. PubMed ID: 35246057
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Myasthenia gravis (MG): epidemiological data and prognostic factors.
    Mantegazza R; Baggi F; Antozzi C; Confalonieri P; Morandi L; Bernasconi P; Andreetta F; Simoncini O; Campanella A; Beghi E; Cornelio F
    Ann N Y Acad Sci; 2003 Sep; 998():413-23. PubMed ID: 14592909
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Some clinico-immunological aspects in patients with ocular myasthenia gravis associated with inflammatory bowel disease.
    Cojocaru IM; Cojocaru M; Tănăsescu R; Burcin C; Atanasiu AN; Mitu AC; Iliescu I; Dumitrescu L
    Rom J Intern Med; 2008; 46(2):165-8. PubMed ID: 19284089
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic predictors of remission in ocular myasthenia after thymectomy.
    Liu X; Zhou W; Hu J; Hu M; Gao W; Zhang S; Zeng W
    J Thorac Dis; 2020 Mar; 12(3):422-430. PubMed ID: 32274108
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Update on Ocular Myasthenia Gravis.
    Smith SV; Lee AG
    Neurol Clin; 2017 Feb; 35(1):115-123. PubMed ID: 27886889
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serum irisin levels in patients with myasthenia gravis.
    Zhang SN; Li Q; Zhang QX; Gao TX; Chang SH; Zhang DQ; Zhang LJ; Yang L
    Neurol Sci; 2022 Apr; 43(4):2785-2790. PubMed ID: 34709479
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Thymectomy and Risk of Generalization in Patients with Ocular Myasthenia Gravis: A Multicenter Retrospective Cohort Study.
    Li H; Ruan Z; Gao F; Zhou H; Guo R; Sun C; Xu Q; Lu Q; Zhou Y; Zhao Z; Yu L; Wu S; Lei T; Gao T; Tang Y; Li C; Huo F; Zhu Y; Sun J; Tang B; Zhang M; Gao Y; Lu X; Li Z; Chang T
    Neurotherapeutics; 2021 Oct; 18(4):2449-2457. PubMed ID: 34625864
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Update on Ocular Myasthenia Gravis.
    O'Hare M; Doughty C
    Semin Neurol; 2019 Dec; 39(6):749-760. PubMed ID: 31847046
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ocular myasthenia gravis - How effective is low dose prednisone long term?
    Verma R; Wolfe GI; Kupersmith MJ
    J Neurol Sci; 2021 Jan; 420():117274. PubMed ID: 33360170
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pediatric Ocular Myasthenia Gravis.
    Fisher K; Shah V
    Curr Treat Options Neurol; 2019 Sep; 21(10):46. PubMed ID: 31559492
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Duke myasthenia gravis clinic registry: I. Description and demographics.
    Sanders DB; Raja SM; Guptill JT; Hobson-Webb LD; Juel VC; Massey JM
    Muscle Nerve; 2021 Feb; 63(2):209-216. PubMed ID: 33205437
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Correlation of anti-acetylcholine receptor antibody levels and long-term outcomes of juvenile myasthenia gravis in Taiwan: a case control study.
    Chou CC; Su IC; Chou IJ; Lin JJ; Lan SY; Wang YS; Kong SS; Chen YJ; Hsieh MY; Hung PC; Wang HS; Chou ML; Lin KL;
    BMC Neurol; 2019 Jul; 19(1):170. PubMed ID: 31319795
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis.
    Jacob S; Viegas S; Leite MI; Webster R; Cossins J; Kennett R; Hilton-Jones D; Morgan BP; Vincent A
    Arch Neurol; 2012 Aug; 69(8):994-1001. PubMed ID: 22689047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.